Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00221039 · ClinicalTrials.gov registry record · Phase 4
Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A
A Phase 4 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT00221039: Completed Phase 4 study, sponsored by M.D. Anderson Cancer Center.
NCT00221039 is a Phase 4 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00221039, a Phase 4 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
The study objective is to demonstrate that the UVADEX® Sterile Solution formulation of methoxsalen used in conjunction with the UVAR XTS Photopheresis System can have a clinical effect on the skin manifestations of CTCL (mycosis fungoides) in early stage disease.
Interventions
- DRUG Methoxsalen+ECP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2004-04-02 |
| Est. Completion | 2011-04-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00221039
The ClinicalTrials.gov registry entry for NCT00221039 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Methoxsalen+ECP is the first listed.
NCT00221039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00221039 about?
NCT00221039 is a clinical study titled "Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A". The study objective is to demonstrate that the UVADEX® Sterile Solution formulation of methoxsalen used in conjunction with the UVAR XTS Photopheresis System can have a clinical effect on the skin manifestations of CTCL (mycosis fungoides) in early stage disease.
What is the current status of trial NCT00221039?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2004-04-02. Estimated completion is 2011-04-05.
What interventions are being tested in trial NCT00221039?
The interventions under investigation include: Methoxsalen+ECP (DRUG).
Who is sponsoring clinical trial NCT00221039?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.